Narayan Pharmaceuticals Pvt. Ltd. - Due diligence report

A 360° intelligence report on Narayan Pharmaceuticals Pvt. Ltd.: trust score, financial health, credit view, compliance, directors, growth a…

1993-01-01 Bhubaneswar, Orissa Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Narayan Pharmaceuticals Pvt. Ltd. — 360° Intelligence Report

Generated from MCA filings & public records
74/100
Trust Score
Moderate

Narayan Pharmaceuticals Pvt. Ltd. is assessed as Moderate with a Trust Score of 74/100. Narayan Pharmaceuticals Pvt. Ltd. is an active private limited indian non-government company incorporated in 1993, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 23 Oct 2026 from the latest processed filings. Narayan Pharmaceuticals Pvt. Ltd. snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
74/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 2 open (44.55 Lakh) · 1 satisfied (49.00 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India1 48.0 cr
Others1 48.0 cr
Indian Overseas Bank1 48.0 cr
Compliance Score: 68/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • Litigation present in 1 court forum(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
ANANTA PRASAD MISHRA 01234567 Director 01/04/2018 6 yrs Approved
ANIL PRASAD MISHRA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • ANANTA PRASAD MISHRA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: ANANTA PRASAD MISHRA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 38%.
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
Operating for 33+ years.
Distress signals & risk flags
Statutory filings appear overdue.
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment59/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 44.55 Lakh already registered.
  • Compliance gaps should be priced into terms.
Investor view72/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 10 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
02 Mar 2019
Securities allotted
150000 Equity Shares - 15.00 Lakh raised
28 Aug 2015
Charge created
Others - 32.55 Lakh
27 Jul 2010
Charge created
Indian Overseas Bank - 12.00 Lakh
21 Nov 2006
Charge satisfied
State Bank Of India
22 Jul 1998
Charge created
State Bank Of India - 49.00 Lakh
01 Jan 1993
Incorporated
Registered with Roc Cuttack
Director appointed
ANANTA PRASAD MISHRA (Managing Director)
Director appointed
ANIL PRASAD MISHRA (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
2 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Blue Jwel Private Limited U74900MH2016PTC274302 Mumbai, Maharashtra, India
Fit N Fine Body Care Services Private Limited U51109WB1995PTC075307 Kolkata, West Bengal, India
Aakrati Transocean Private Limited U24302RJ1997PTC014469 Udaipur, Rajasthan, India
Saroc Technology India Private Limited U74999TN2018PTC120977 Ramanathapuram, Tamil Nadu, India
Maruti Laminates Private Limited U20211GJ2008PTC052794 Daskroi, Gujarat, India
Kansal Buildtech Equipment Private Limited U70109DL2006PTC151825 New Delhi, Delhi, India
Wiona Electricals Private Limited U52609TG2020PTC146378 Hyderabad, Telangana, India
Legame Infratech Private Limited U93000MH2017PTC299535 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Narayan Pharmaceuticals Pvt. Ltd. before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Narayan Pharmaceuticals Pvt. Ltd.: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Narayan Pharmaceuticals Pvt. Ltd. - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 74/100, distress signals and MSME payment-delay disclosures - know whether Narayan Pharmaceuticals Pvt. Ltd. pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Narayan Pharmaceuticals Pvt. Ltd. - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Narayan Pharmaceuticals Pvt. Ltd. an active company?

Narayan Pharmaceuticals Pvt. Ltd. has MCA status “Active” with a compliance score of 68/100 (Moderate).

Is Narayan Pharmaceuticals Pvt. Ltd. financially healthy?

Narayan Pharmaceuticals Pvt. Ltd. has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Narayan Pharmaceuticals Pvt. Ltd.?

Its overall Trust Score is 74/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Narayan Pharmaceuticals Pvt. Ltd.?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Narayan Pharmaceuticals Pvt. Ltd. have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Narayan Pharmaceuticals Pvt. Ltd. up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 68/100 (Moderate).

Is it risky to lend to Narayan Pharmaceuticals Pvt. Ltd.?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.